Monday, October 3, 2022


Biotechnology News Magazine

Aquavit to Introduce A New Botulinum Toxin

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

April 14, 2021

Aquavit Holdings LLC announced today that it acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in the United States and Canada.

For several years, Aquavit has been investing in its proprietary delivery technologies and related intellectual property for botulinum toxin and recently proved its efficacy and safety through a clinical study. It also compared and evaluated optimal dosing with three FDA approved botulinum toxins with varying injection depths and widths.

According to a published article by the American Society for Dermatologic Surgery (ASDS), the licensed asset DTX-021 showed equivalency on glabellar lines and improvement on periorbital rhytids compared to onabotulinumtoxinA (BOTOX®) in a multicenter, double-blind, randomized, parallel, active-controlled phase III clinical trial. There were no adverse events.

The manufacturing partner is Huons Bio Pharma (“Huons”),  a spin-off from the publicly traded South Korean corporation Huons Global Co. Ltd. [KOSDAQ: 084110]

With this deal, Huons will receive sizable milestone payments and royalties in addition to an upfront payment, and become the exclusive supplier of Aquavit’s botulinum toxin. Aquavit plans to initiate the registration process by filing an IND with the FDA shortly.

“We are thrilled to partner with Huons for this venture. Together, we will introduce the most innovative botulinum toxin product, and uplift and modernize the treatment paradigm,” said Sobin Chang, CEO of Aquavit.

According to The Aesthetic Society and the Global Market Insights, botulinum toxin has been the #1 non-surgical aesthetic procedure since 1999 and is still growing rapidly. The North America botulinum toxin market alone was valued at $3.19B in 2019. With a projected CAGR of 7-9%, the global botulinum toxin market in 2026 is expected to be $8.9B

Aquavit’s proven track record of developing and launching a global brand such as AQUAGOLD®, combined with its knowledge of the botulinum toxin market, and its network of over 20,000 physicians worldwide who use botulinum toxin products, can make a significant impact in the fast growing market with only 4 companies with an FDA approval today,” said Marc Toulemonde, Aquavit’s board member and an industry leader in top beauty and aesthetic brands.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine